The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age

Simple item page
dc.contributor.authorErez, Offer
dc.contributor.authorRomero, Roberto
dc.contributor.authorEspinoza, Jimmy
dc.contributor.authorFu, Wenjiang
dc.contributor.authorTodem, David
dc.contributor.authorKusanovic, Juan Pedro
dc.contributor.authorGotsch, Francesca
dc.contributor.authorEdwin, Samuel
dc.contributor.authorNien, Jyh Kae
dc.contributor.authorChaiworapongsa, Tinnakorn
dc.contributor.authorMittal, Pooja
dc.contributor.authorMazaki Tovi, Shali
dc.contributor.authorThan, Nandor Gabor
dc.contributor.authorGomez, Ricardo
dc.contributor.authorHassan, Sonia S.
dc.date.accessioned2024-01-10T12:09:23Z
dc.date.available2024-01-10T12:09:23Z
dc.date.issued2008
dc.description.abstractIntroduction. An imbalance between angiogenic and anti-angiogenic factors has been proposed as central to the pathophysiology of preeclampsia (PE). Indeed, patients with PE and those delivering small-for-gestational age (SGA) neonates have higher plasma concentrations of soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) and the soluble form of endoglin (s-Eng), as well as lower plasma concentrations of vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) than do patients with normal pregnancies. Of note, this imbalance has been observed before the clinical presentation of PE or the delivery of an SGA neonate. The objective of this study was to determine if changes in the profile of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters are associated with a high risk for the subsequent development of PE and/or delivery of an SGA neonate.
dc.description.abstractMethods. This longitudinal case-control study included 402 singleton pregnancies in the following groups: (1) normal pregnancies with appropriate for gestational age (AGA) neonates (n=201); (2) patients who delivered an SGA neonate (n=145); and (3) patients who developed PE (n=56). Maternal plasma samples were obtained at the time of each prenatal visit, scheduled at 4-week intervals from the first or early second trimester until delivery. In this study, we included two samples per patient: (1) first sample obtained between 6 and 15 weeks of gestation ('first trimester' sample), and (2) second sample obtained between 20 and 25 weeks of gestation ('second trimester' sample). Plasma concentrations of s-Eng, sVEGFR-1, and PlGF were determined by specific and sensitive immunoassays. Changes in the maternal plasma concentrations of these angiogenesis-related factors were compared among normal patients and those destined to develop PE or deliver an SGA neonate while adjusting for maternal age, nulliparity, and body mass index. General linear models and polytomous logistic regression models were used to relate the analyte concentrations, ratios, and product to the subsequent development of PE and SGA.
dc.description.abstractResults. (1) An increase in the maternal plasma concentration of s-Eng between the first and second trimesters conferred risk for the development of preterm PE and SGA (OR 14.9, 95% CI 4.9-45.0 and OR 2.9, 95% CI 1.5-5.6, respectively). (2) An increase in the maternal plasma concentration of sVEGFR-1 between the first and second trimester conferred risk for the development of preterm PE (OR 3.9, 95% CI 1.2-12.6). (3) A subnormal increase in maternal plasma PlGF concentration between the first and the second trimester was a risk factor for the subsequent development of preterm and term PE (OR 4.3, 95% CI 1.2-15.5 and OR 2.7, 95% CI 1.2-5.9, respectively). (4) In addition, the combination of the three analytes into a pro-angiogenic versus anti-angiogenic ratio (PlGF/(s-EngVEGFR-1)) conferred risk for the subsequent development of preterm PE (OR 3.7, 95% CI 1.1-12.1). (5) Importantly, patients with a high change in the s-EngsVEGFR-1 product had an OR of 10.4 (95% CI 3.2-33.8) for the development of preterm PE and 1.6 (95% CI 1.0-2.6) for the development of SGA.
dc.description.abstractConclusions. Changes in the maternal plasma concentrations of s-Eng, sVEGFR-1, PlGF or their ratios between the first and second trimesters of pregnancy confer an increased risk to deliver an SGA neonate and/or develop PE.
dc.description.funderEUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT
dc.description.funderIntramural NIH HHS
dc.format.extent9 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1080/14767050802034545
dc.identifier.eissn1476-4954
dc.identifier.issn1476-7058
dc.identifier.pubmedidMEDLINE:18446652
dc.identifier.urihttps://doi.org/10.1080/14767050802034545
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/76485
dc.identifier.wosidWOS:000255435500001
dc.information.autorucMedicina;Gómez R;S/I;80926
dc.issue.numero5
dc.language.isoen
dc.nota.accesoSin adjunto
dc.pagina.final287
dc.pagina.inicio279
dc.publisherTAYLOR & FRANCIS LTD
dc.revistaJOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
dc.rightsregistro bibliográfico
dc.subjectSGA
dc.subjectlongitudinal
dc.subjectPlGF
dc.subjectendoglin
dc.subjectsVEGFR-1
dc.subjectENDOTHELIAL GROWTH-FACTOR
dc.subjectUTERINE ARTERY DOPPLER
dc.subjectBODY-MASS INDEX
dc.subjectFACTOR RECEPTOR-1 CONCENTRATION
dc.subjectTYROSINE KINASE-1
dc.subjectSOLUBLE ENDOGLIN
dc.subjectNORMAL-PREGNANCY
dc.subjectANTIANGIOGENIC FACTORS
dc.subjectSERUM-LEVELS
dc.subjectPLACENTA
dc.subject.ods05 Gender Equality
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa05 Igualdad de género
dc.subject.odspa03 Salud y bienestar
dc.titleThe change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age
dc.typeartículo
dc.volumen21
sipa.codpersvinculados80926
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Collections
Artículos de revistas